Target Name: CD99L2
NCBI ID: G83692
Review Report on CD99L2 Target / Biomarker Content of Review Report on CD99L2 Target / Biomarker
CD99L2
Other Name(s): MIC2-like protein 1 | C99L2_HUMAN | CD99 | CD99 molecule like 2 | CD99B | MIC2L1 | CD99 antigen-like protein 2 | CD99 antigen-like protein 2 (isoform 1) | CD99L2 variant 1 | MIC2 like 1

CD99L2: A Potential Drug Target and Biomarker for Cancer

Introduction

Cancer is one of the leading causes of human mortality, with over 20 million new cases being diagnosed every year worldwide. The development of effective cancer treatments is crucial for improving patient outcomes. One promising approach to cancer treatment is the targeted inhibition of oncogenic proteins, such as CD99L2, which has been identified as a potential drug target and biomarker for cancer.

CD99L2: Structure and Function

CD99L2 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and gastrointestinal tract. It is a member of the integrin receptor family, which includes proteins that are involved in cell-cell and cell -tissue interactions, as well as in cell signaling pathways.

CD99L2 is characterized by its unique N-terminus that contains a farnesylated cysteine 鈥嬧?媟esidue, which is important for its stability and functions as a critical structural protein. The CD99L2 protein is also known for its unique C-terminus that contains a conserved GXXGXXG motif, which is involved in its stability and functions as a critical structural protein.

CD99L2 has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and invasion. It is also involved in cell signaling pathways, including the TGF-β pathway. This pathway is known to be involved in the development and Progression of many types of cancer, including breast, lung, and colorectal cancers.

CD99L2 has also been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps cells eliminate themselves when they are no longer needed. The loss of CD99L2 has been linked to the development of cancer, suggesting that it may be a promising biomarker for cancer.

CD99L2 as a Drug Target

The potential of CD99L2 as a drug target is based on its involvement in various cellular processes that are involved in cancer development. One of the main strategies to target CD99L2 is the inhibition of its activity by small molecules, such as drugs that can bind to specific CD99L2 functions.

One of the most promising CD99L2 inhibitors is a small molecule called curcumin, which is an antioxidant that is derived from turmeric, a common spice. Curcumin has been shown to have anti-inflammatory and anti-tumor effects, and it is thought to work by inhibiting the activity of CD99L2.

Another promising CD99L2 inhibitor is a drug called sunitinib, which is an inhibitor of the tyrosine kinase TKT. TKT is a critical enzyme involved in the TGF-β pathway, which is involved in cancer development. Sunitinib has been shown to be an effective inhibitor of TKT and has been shown to have anti-cancer effects in various types of cancer.

CD99L2 as a Biomarker

CD99L2 has also been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps cells eliminate themselves when they are no longer needed. The loss of CD99L2 has been linked to the development of cancer, suggesting that it may be a promising biomarker for cancer.

One of the most promising approaches to using CD99L2 as a biomarker is the measurement of cell apoptosis in cancer cells. This can be done by measuring the levels of the protein Bax, which is involved in

Protein Name: CD99 Molecule Like 2

Functions: Plays a role in a late step of leukocyte extravasation helping cells to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1 (By similarity). Homophilic adhesion molecule, but these interactions may not be required for cell aggregation (By similarity)

The "CD99L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD99L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20